7 Mar 2021
New Data Show NEXTSTELLIS® Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives
Author: admintech | Filed under: Press ReleaseRALEIGH, N.C., March 6, 2021 /PRNewswire/ — Mayne Pharma announced today new data showing treatment with NEXTSTELLIS®,1 a novel, investigational combined oral contraceptive (COC) containing drospirenone (DRSP) and estetrol (E4), resulted in limited changes in endocrine markers, including…